From GlobeNewswire:

Orion presented more results from the phase II CYPIDES study, evaluating the safety and efficacy of ODM-208/MK-5684 oral treatment on patients with metastatic castration-resistant prostate cancer who have undergone multiple different cancer treatments. ODM-208/MK-5684 has shown promising results in decreasing PSA levels and inhibiting cancer cell growth, particularly in patients with the AR-LBD mutation. This study is part of phase III clinical trials to further evaluate its benefits. Contact Terhi Ormio, Communication Director, for more information.

ODM-208/MK-5684 is an investigational oral therapy developed by Orion for hormone-dependent cancers, including prostate cancer, in collaboration with MSD. The treatment is currently being assessed in two phase III clinical trials, OMAHA1 and OMAHA2a. The treatment is designed for patients with metastatic castration-resistant prostate cancer alongside hormone replacement therapy. For more information, visit Orion’s official website.



Read more: Lisää tuloksia ODM-208/MK-5684:llä tehtävästä vaiheen